Global Nanomedicine Market: Key Developments
Major players in the global nanomedicine market are focused on R&D of new products to expand their product portfolio. For instance, in June 2020, Nanobiotix S.A announced that the FDA has provided necessary feedback regarding the design of NANORAY-312, the company’s pivotal phase III global registration trial in head and neck cancer.
Similarly, in June 2020, Cellics Therapeutics, Inc. announced that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters.
Investment in nanomedicine is expected to propel growth of the global nanomedicine market. For instance, in July 2020, Curadigm SAS, a wholly-owned subsidiary of Nanobiotix S.A., announced the receipt of US$ 1.18 million in non-dilutive funding from Deep Tech BPI France for the development of their Nanoprimer technology.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients